erlotinib hydrochloride has been researched along with oligonucleotides in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (oligonucleotides) | Trials (oligonucleotides) | Recent Studies (post-2010) (oligonucleotides) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 23,128 | 245 | 7,331 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D | 1 |
| Beraldi, E; Fazli, L; Gleave, ME; Ionescu, DN; Kumano, M; Lelj-Garolla, B; Nappi, L; Rocchi, P; Zoubeidi, A | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
2 trial(s) available for erlotinib hydrochloride and oligonucleotides
| Article | Year |
|---|---|
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome | 2014 |
2 other study(ies) available for erlotinib hydrochloride and oligonucleotides
| Article | Year |
|---|---|
Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Molecular Chaperones; Oligonucleotides; Xenograft Model Antitumor Assays | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |